Kala Pharmaceuticals Co-founder Publishes Data on Novel Therapeutic Approach to Overcome Mucosal Barrier for Prevention of Herpes Simplex Virus-2 Infection

<0> Results in Demonstrate Ability of Mucosal-Penetrating Products (MPPs) to Achieve Retained Drug Levels and Enhanced Efficacy at the Site of Disease </0>

Kala Pharmaceuticals Co-founder Publishes Data on Novel Therapeutic Approach to Overcome Mucosal Barrier for Prevention of Herpes Simplex Virus-2 Infection

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat a wide range of debilitating diseases, announced a publication by company co-founder Justin Hanes, PhD in showing promising effects of its Mucosal-Penetrating Products (MPPs) in preventing Herpes Simplex Virus-2 (HSV-2) infection.

In the paper titled “Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus,” Dr. Hanes and collaborators at Johns Hopkins University School of Medicine conducted preclinical studies that included acyclovir-MPP, Kala’s innovative therapeutic engineered with the anti-HSV drug, acyclovir. The studies demonstrated that MPPs improve mucus penetration and drug retention, enabling the acyclovir-MPP to achieve greater efficacy at one tenth of the dose compared to conventional acyclovir.

“Mucosal barriers have been largely overlooked as a limitation for drug efficacy. These data show how Kala’s MPP approach can open up new possibilities for more effective medicines,” commented Robert Langer, ScD, another Kala co-founder and the David H. Koch Institute Professor at MIT. “Kala’s technology can be used to engineer innovative therapies with the size and surface coating properties necessary to dramatically improve drug penetration and retention in mucosal tissues leading to the potential for significantly enhanced therapeutic outcomes.”

Key findings of the published study include:

“These results from Dr. Hanes’ lab at Johns Hopkins University are very encouraging and further expand on previous proof-of-concept studies with Kala’s MPPs in other mucosal tissues including our NIH-sponsored work in the eye and respiratory tract,” said Guillaume Pfefer, PhD, CEOof Kala Pharmaceuticals. “These data show the significant impact that Kala’s therapeutic approach can have in creating highly effective treatments for debilitating respiratory, ophthalmic, female reproductive tract and gastrointestinal diseases.”

Kala Pharmaceuticals, Inc. is developing innovative products which are capable of penetrating mucosal barriers for the treatment of major diseases that affect the eyes, lungs, gastrointestinal tract, and female reproductive system. Mucosal barriers have been largely overlooked as a limitation for drug efficacy. Using the company’s proprietary technology platform, Kala’s Mucosal-Penetrating Products (MPPs) have the unique ability to rapidly and uniformly coat and permeate mucosal tissues leading to highly effective treatments with improved side effect profiles. The company is leveraging its platform as an internal product engine for a wide spectrum of potential applications, including treatments for respiratory, ophthalmic female reproductive tract and gastrointestinal diseases. Kala is also pursuing collaborations with partners to transform the therapeutic properties of marketed drugs and compounds in development. Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, Dr. Justin Hanes of The Johns Hopkins University School of Medicine, Dr. Robert Langer of the Massachusetts Institute of Technology, and Dr. Colin Gardner formerly of TransForm Pharmaceuticals/Johnson & Johnson and Merck. The company is backed by leading investors including Lux Capital, Polaris Venture Partners, and Third Rock Ventures. For more information, please visit .

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.